- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06418113
Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma (GLINERA)
The goal of this clinical trial is to evaluate the safety and efficacy of neoadjuvant radiochemotherapy in the surgical resection of glioblastoma (GBM). The main questions it aims to answer are:
- What is the safety profile of neoadjuvant radiochemotherapy in terms of neurological deficit, radionecrosis, edema, headache, wound dehiscence, infection, and cerebrospinal fluid fistula?
- What is the efficacy of neoadjuvant radiochemotherapy in terms of progression-free survival, overall survival, cognitive function, and quality of life?
Participants will undergo the following tasks and treatments:
- Stereotactic biopsy and diagnosis confirmation.
- Conformal hypofractionated stereotactic radiotherapy with concurrent temozolomide.
- Supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring.
- Maintenance temozolomide administration for 6 months.
Researchers will compare the group receiving neoadjuvant radiochemotherapy to the control group following the standard Stupp protocol to assess safety and efficacy outcomes.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Juan Antonio Barcia
- Phone Number: +34 913303506
- Email: jabarcia@ucm.es
Study Contact Backup
- Name: Mª Rebeca Lliguin León
- Phone Number: +34 622059861
- Email: rebeca.lliguin.leon@gmail.com
Study Locations
-
-
-
Madrid, Spain, 28040
- Recruiting
- Hospital Clinico San Carlos
-
Contact:
- Juan Antonio Barcia
- Phone Number: +34 913303506
- Email: jabarcia@ucm.es
-
Contact:
- Mª Rebeca Lliguin León
- Phone Number: 622059861
- Email: rebeca.lliguin.leon@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 and 75 years.
- Unifocal disease.
- Unilobar tumor.
- Clinical-radiological diagnosis of supratentorial unicentric high-grade glioma, eligible for macroscopically complete resection.
Exclusion Criteria:
- Multilobar tumor, interhemispheric or infratentorial extension, or multifocal disease.
- Midline shift greater than 1 cm.
- Intracranial hypertension symptoms requiring corticosteroid treatment.
- Synchronous neoplasia.
- Any contraindication for surgery, radiotherapy, or TMZ treatment.
- Cognitive impairment.
- Rejection of informed consent.
- Inability to follow up for 2 years.
- Women of childbearing potential according to the Clinical Trial Facilitation Group (CTFG) criteria. (https://www.hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2020_09_HMA_CTFG_Contraception_guidance_Version_1.1.pdf)
- Hypersensitivity to the active ingredient or any excipients of the investigational drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Stereotactic biopsy will be performed on patients in the experimental group, who will then be discharged.
If the histopathological diagnosis is not wildtype IDH non-mutated glioblastoma, the patient will be withdrawn from the study and receive conventional treatment.
If wildtype IDH non-mutated glioblastoma is diagnosed, ten days after the biopsy, patients will undergo conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period (GEINO, 2016).
Five weeks later, patients will undergo supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring.
Starting from 4 weeks post-surgery, TMZ will be administered for 6 months according to the Stupp protocol.
|
conformal hypofractionated stereotactic radiotherapy to the FLAIR hyperintense signal, including the contrast-enhancing tumor on T1, with a total dose of 3990 cGy at the margin in 15 fractions of 266 cGy, one session per day, five days a week, and concurrent temozolomide (TMZ) at 75 mg/m2/day for 7 days/week during the irradiation period
Stereotactic biopsy
supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
4 weeks post-surgery, temozolomide (TMZ) will be administered for 6 months
|
Other: Stupp Protocol
The Stupp protocol is a standard treatment regimen for glioblastoma, which involves a combination of radiotherapy and chemotherapy.
|
supramarginal resection guided by 5-ALA under intraoperative neurophysiological monitoring
radiotherapy + TMZ concurrently after 4 weeks of resection surgery, as per usual protocol: Three-dimensional radiotherapy planning to deliver a total dose of 60 Gy, with a fractionation of 2 Gy/day, 5 days/week, encompassing a 1-2 cm margin around the contrast-enhancing region defined on T1 imaging or the entire abnormal volume defined on T2 or FLAIR imaging (Li et al., 2016) + TMZ at 75 mg/m2/day for 7 days/week, for 6 weeks during radiotherapy.
temozolomide (TMZ) will be administered for 6 months according to the Stupp protocol.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Emergent Adverse Events assessed by physical and neurological examination
Time Frame: Clinical follow-up every month for 2 years
|
Information on adverse events will be reviewed through direct questioning of the patient.
|
Clinical follow-up every month for 2 years
|
Emergent Adverse Events assessed by evaluation of the results of the analysis with hematology and biochemistry.
Time Frame: Clinical follow-up every month for 2 years
|
Information on adverse events will be reviewed through the results of examinations, complementary tests and analytical parameters.
|
Clinical follow-up every month for 2 years
|
Emergent Adverse Events assessed by brain RM image
Time Frame: every 3 months after surgery, for 2 years
|
brain RM image, for neuroradiological follow-up
|
every 3 months after surgery, for 2 years
|
Emergent Adverse Events assessed by AC_PET with 18-FdG
Time Frame: every 6 months after surgery, for 2 years
|
AC_PET image, for neuroradiological follow-up
|
every 6 months after surgery, for 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy assessed by progression-free survival (PFS)
Time Frame: through study completion, an average of 2 yeas.
|
Progression-free survival (PFS), a measure of how long a patient receives treatment before the cancer begins to grow.
|
through study completion, an average of 2 yeas.
|
Efficacy assessed by overall survival (OS)
Time Frame: through study completion, an average of 2 yeas.
|
Overall survival (OS), how long patients live after starting treatment.
|
through study completion, an average of 2 yeas.
|
Quality of life assessed by The Functional Assessment of Cancer Therapy-Brain (FACT-Br)
Time Frame: every 3 months after surgery, for 2 years
|
A commonly used instrument measuring general quality of life (QOL) that reflects symptoms or problems associated with brain malignancies across 5 scales.
Patients rate all 5 items using a five-point Likert scale ranging from 0 "not at all" to 4 "very much."
Overall, higher ratings suggest higher QOL
|
every 3 months after surgery, for 2 years
|
Cognitive functionality assessed by MONTREAL COGNITIVE ASSESSMENT (MOCA)
Time Frame: every 3 months after surgery, for 2 years
|
It has been shown to be useful at detecting cognitive dysfunction in brain metastases. The test is a one-page, 30-point test that can be administered in 10 minutes. It assesses short-term memory recall (5 points), visuospatial abilities through clock-drawing (3 points) and cube copy (1 point), and orientation (6 points). Executive function is assessed through modified Trail Making Part B (1 point), phonemic fluency (1 point), and verbal abstraction (2 points). A sustained-attention task (1 point), digit span (2 points), and serial calculation (3 points) test attention, concentration, and working memory. And lastly, language is assessed through naming low-familiarity animals (3 points), sentence repetition (2 points), and the fluency task |
every 3 months after surgery, for 2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22/399
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial ComponentUnited States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
Clinical Trials on hypofractionated stereotactic radiotherapy
-
Huashan HospitalActive, not recruiting
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaTerminated
-
Chang Gung Memorial HospitalRecruitingBrain Metastases, AdultTaiwan
-
Barretos Cancer HospitalWithdrawnCancer | MetastasisBrazil
-
National Taiwan University HospitalUnknownMetastasis of Malignant Neoplasm to Lymph NodeTaiwan
-
Centre Jean PerrinGORTECActive, not recruitingHead and Neck NeoplasmsFrance
-
Technical University of MunichRecruitingBrain Metastases | Resection CavityGermany
-
Barretos Cancer HospitalWithdrawn
-
Susanne RogersUniversity of Basel; Technical University of MunichRecruitingBrain Metastases, AdultSwitzerland
-
Centre Francois BaclesseAssociation de Neuro-Oncologues d'Expression FrancaiseActive, not recruitingBrain Metastasis | OligoprogressionFrance